- £214.94bn
- £234.65bn
- $58.74bn
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal (updated)
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
European shares close lower as investors weigh Middle East risks (updated)
European shares steady; Middle East tensions in focus
UK Stocks-Factors to watch on June 9 (updated)
UK Stocks-Factors to watch on June 9
Press Digest: Financial Times - June 9
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial
Brief: Astrazeneca-Ultomiris Demonstrated 43.4% Reduction In Proteinuria Versus Placebo In Adults With Immunoglobulin A Nephropathy At 34 Weeks In Phase III Trial
Media: AstraZeneca chief warns group could withhold new drugs in Europe-FT
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Celcuity rises after boosted $500 mln convertible bond offering
Celcuity drops further after announcing $400 mln convertible offering
'It's still working': More are living with cancer as era of targeted drugs takes hold